Loading clinical trials...

Therapeutic Plasma Exchange in MG | Clinical Trials | Clareo Health

COMPLETEDNCT01927692

Therapeutic Plasma Exchange in MG

The primary objective of the study is to longitudinally profile immunoglobulin levels and autoantibody levels in subjects with myasthenia gravis (MG) who receive therapeutic plasma exchange (TPE).

Lead sponsor: Duke University•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITING

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644 · Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, and more

RECRUITINGNA

TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls

NCT06754020 · Myasthenia Gravis

RECRUITINGPhase 1/2

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

NCT07089121 · Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), and more

RECRUITINGPhase 4

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

NCT07246564 · Myasthenia Gravis

RECRUITING

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

NCT07247279 · Rare Diseases, Generalized Myasthenia Gravis (gMG)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 16, 2015Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment11

Start dateJul 2013

Last updatedJul 16, 2015

Condition

Myasthenia Gravis

Locations shown

UNC Chapel Hill

Chapel Hill, North Carolina

Duke University Hospital

Durham, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 16, 2015Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions